Nivolumab Shows Encouraging Survival Rates in Heavily Pretreated Lung Cancer
Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated non-small cell lung cancer (NSCLC).
Diagnosis & Disease Information
Pembrolizumab Shows Promise in Non-Small Cell Lung Cancer
Programmed cell death 1 (PD-1) inhibition with pembrolizumab is showing early promise for some patients with advanced non-small-cell lung cancer.
Pseudomonas Preparation May Improve Response Rate in Lung Cancer
Pseudomonas aeruginosa preparation (PAP) with chemotherapy may improve response rate in patients with non-small cell lung cancer (NSCLC).
In Non-Small Cell Lung Cancer, Pulmonologist Management Beneficial
For non-small-cell lung cancer (NSCLC), pulmonologist management is positively associated with rates of stage-specific treatment.
Platinum Chemo in NSCLC Linked with Lower Mortality, More Adverse Events
Platinum-based adjuvant chemotherapy is associated with reduced mortality, increased risk of adverse events in elderly non-small cell lung cancer (NSCLC).
Pemetrexed Can Replace Carboplatin in Standard NSCLC Therapy, Small Phase 2 Study Suggests
Pemetrexed can replace platinum compounds such as carboplatin in first-line standard therapy for non-small cell lung cancer (NSCLC).
Comorbidities Contribute to Death Risk in Lung Cancer Later in Life
Cause of death in NSCLC by comorbidities such as cardiovascular disease and chronic obstructive pulmonary disease (COPD) increase with time.
Trametinib Shows Similar Benefit to Docetaxel in Previously Treated NSCLC
Trametinib showed similar survival and response as docetaxel in previously treated KRAS mutation-positive non-small cell lung cancer (NSCLC).
Tecemotide May Be Effective in NSCLC with Concurrent Chemoradiotherapy
Tecemotide may provide treatment benefit in stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy.
Opdivo Approved for Advanced Squamous Non-Small Cell Lung Cancer
The FDA has approved Opdivo (nivolumab) for the treatment of patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...